Skip to Content

Publications Search - Abstract View

Title: Case-control study of arsenic in drinking water and kidney cancer in uniquely exposed Northern Chile.
Authors: Ferreccio C,  Smith AH,  Durán V,  Barlaro T,  Benítez H,  Valdés R,  Aguirre JJ,  Moore LE,  Acevedo J,  Vásquez MI,  Pérez L,  Yuan Y,  Liaw J,  Cantor KP,  Steinmaus C
Journal: Am J Epidemiol
Date: 2013 Sep 1
Branches: OEEB
PubMed ID: 23764934
PMC ID: PMC3817454
Abstract: Millions of people worldwide are exposed to arsenic in drinking water. The International Agency for Research on Cancer has concluded that ingested arsenic causes lung, bladder, and skin cancer. However, a similar conclusion was not made for kidney cancer because of a lack of research with individual data on exposure and dose-response. With its unusual geology, high exposures, and good information on past arsenic water concentrations, northern Chile is one of the best places in the world to investigate the carcinogenicity of arsenic. We performed a case-control study in 2007-2010 of 122 kidney cancer cases and 640 population-based controls with individual data on exposure and potential confounders. Cases included 76 renal cell, 24 transitional cell renal pelvis and ureter, and 22 other kidney cancers. For renal pelvis and ureter cancers, the adjusted odds ratios by average arsenic intakes of <400, 400-1,000, and >1,000 µg/day (median water concentrations of 60, 300, and 860 µg/L) were 1.00, 5.71 (95% confidence interval: 1.65, 19.82), and 11.09 (95% confidence interval: 3.60, 34.16) (Ptrend < 0.001), respectively. Odds ratios were not elevated for renal cell cancer. With these new findings, including evidence of dose-response, we believe there is now sufficient evidence in humans that drinking-water arsenic causes renal pelvis and ureter cancer.